Potential therapeutic use of antibodies directed towards HuIFN-gamma.
IFN-gamma is an important regulator of immune responses and inflammation. Studies in animal models of inflammation, autoimmunity, cancer, transplant rejection and delayed-type hypersensitivity have indicated that administration of antibodies against IFN-gamma can prevent the occurrence of diseases or alleviate disease manifestations. Therefore, it is speculated that such antibodies may have therapeutical efficacy in human diseases. Since animal-derived antibodies are immunogenic in patients several strategies are being developed in order to reduce or abolish this human anti-mouse antibody (HAMA) response. In our laboratory, we have constructed a single-chain variable fragment (scFv) derived from a mouse antibody with neutralizing potential for human IFN-gamma. A scFv consists of only variable domains tethered together by a flexible linker. The scFv was demonstrated to neutralize the antiviral activity of HuIFN-gamma in vitro and therefore might be considered as a candidate for human therapy.
Froyen
G
G
Rega Institute for Medical Research, University of Leuven, Belgium.
Billiau
A
A
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D007128:Immunoglobulin Fragments / Q000627:therapeutic use; D007371:Interferon-gamma / Q000276:immunology* / Q000502:physiology; D051379:Mice
D000911:Antibodies, Monoclonal; D007128:Immunoglobulin Fragments; C055966:immunoglobulin Fv; D007371:Interferon-gamma